What is not working for the company?
What is working for the company?
|Name||Dec 22||Sep 22|
|Mutual Funds (Change:-0.00)||0.79%||0.79%|
|Insurance Companies (Change:0.00)||0%||0%|
|Other DIIs (Change:-0.01)||6.22%||6.23%|
|Non Institution (Change:0.07)||39.15%||39.08%|
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in NEULAND LABORATORIES LTD.
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
Frequently Asked Questions
What is the Share price of NEULAND LABORATORIES LTD. (NEULANDLAB)?
Can I buy NEULAND LABORATORIES LTD. (NEULANDLAB) shares?
How do I buy NEULAND LABORATORIES LTD. (NEULANDLAB) from Angel One?
- Direct investment: You can buy NEULAND LABORATORIES LTD. (NEULANDLAB) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to NEULAND LABORATORIES LTD. (NEULANDLAB) shares.
In which sector do NEULAND LABORATORIES LTD. (NEULANDLAB) belong?
Today's live share price for NEULAND LABORATORIES LTD. is NSE: ₹ 1,412.05, BSE: ₹ 1,416.70 with a current market capitalization of .
Set up in 1984 as a private limited company to manufacture bulk drugs, Neuland Laboratories (NLL) is promoted by D R Rao. Neuland Drugs & Pharmaceuticals Pvt Ltd, a company set up by the same promoters to manufacture bulk drugs was merged with NLL with effect from Apr.'92. NLL manufactures bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. It came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.7 cr. NLL's products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate. During the year 1999-2000, the company introduced Itraconazole, an anti-fungal drug and Ipratropium Bromide, an anti-asthmatic drug and the R & D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form. Mirtrazapine, an anti-depressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI. The company is closely working with several companies in Europe and North America for supply of active pharmaceutical ingredients and intermediates.Read more